

I hereby certify that this correspondence is being deposited with the United States Postal Service first class mail in an envelope addressed to: Commissioner for Patents, PO Box 1450 Alexandria, VA 22313-1450, on October 28, 2004



QUINE INTELLECTUAL PROPERTY LAW GROUP, P.C.

By

Chianti Appling

Attorney Docket No. 407T-980910US  
Client Ref. No. 2000-168-3

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Glenn L. Millhauser, et al.

Application No.: 09/851,586

Filed: May 8, 2001

For: METHODS AND COMPOUNDS FOR  
MODULATING MELANOCORTIN  
RECEPTOR LIGAND BINDING  
AND ACTIVITY

Examiner: Carolyn L. Smith

Art Unit: 1631

INFORMATION DISCLOSURE  
STATEMENT UNDER 37 CFR § 1.97 and  
§ 1.98

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

Sir:

The references cited on attached form PTO-1449 are being called to the attention of the Examiner. Copies of the references are enclosed. It is respectfully requested that the cited information be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no

representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

This IDS is being filed after the mailing date of the first Office Action and more than three months after the filing date, but prior to the Notice of Allowance or Final Office Action. Please deduct \$180.00, pursuant to 37 CFR §1.17(p), from the undersigned's Deposit Account No. 50-0893. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,

A handwritten signature in cursive script, appearing to read "Tom Hunter".

Tom Hunter, J.D., Ph.D.  
Reg. No. 38,498

QUINE INTELLECTUAL PROPERTY LAW GROUP, P.C.  
P.O. BOX 458  
Alameda, CA 94501  
(510) 337-7871  
Fax (510) 337-7877

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A-B/PTO

## Complete if Known

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Application Number	09/851,586
Filing Date	May 8, 2001
First Named Inventor	Glenn L. Millhauser
Group Art Unit	1631
Examiner Name	Carolyn L. Smith
Attorney Docket Number	407T-980910US
Date Submitted	October 28, 2004

## U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, lines, Where Relevant Passages or Relevant Figures Appeal
		Number	Kind Code (if known)			
	1	5,622,860		Yamada et al	04/22/1997	
	2	5,703,220		Yamada et al	12/30/1997	
	3	5,731,408		Hadley et al	03/24/1998	
	4	5,766,877		Stark et al	06/16/1998	
	5	5,817,787		Yamada et al	10/06/1998	
	6	5,843,652		Woychik	12/01/1998	
	7	5,869,257		Yamada et al	02/09/1999	
	8	5,932,779		Lee et al	08/03/1999	
	9	5,994,087		Cone et al	11/30/1999	

## FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office	Number	Kind Code (if known)				
	10	WO	99/43709					
	11	WO	99/64002		Merk & Co.	12/16/1999		
	12	WO	99/57148		WA Pharm AB	11/11/1999		
	13	WO	99/55679		Trega Biosciences	11/04/1999		
	14	WO	99/55832		Merk & Co.	11/04/1999		
	15	WO	99/54358		Quadrant Holdings	10/28/1999		
	16	WO	99/43709		Regents of the University of CA	09/02/1999		
	17	WO	99/31508		Merk & Co.	06/24/1999		
	18	WO	99/21571		Trega Biosciences	05/06/1999		
	19	WO	98/56914		Oregon Health Sci	12/17/1998		
	20	WO	98/10068		Oregon Health Sci	03/12/1998		
	21	WO	97/43412		Amgen Inc.	11/20/1997		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A-B/PTO

Complete if Known

Application Number	09/851,586
Filing Date	May 8, 2001
First Named Inventor	Glenn L. Millhauser
Group Art Unit	1631
Examiner Name	Carolyn L. Smith
Attorney Docket Number	407T-980910US
Date Submitted	October 28, 2004

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(use as many sheets as necessary)

## OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	22	Fakete <i>et al.</i> (2004) Endocrinology, online publication: doi:10.1210/en.2004-0476	
	23	Fong, <i>et al.</i> (1997) <i>Biochem. Res. Commun.</i> 237:629-611	
	24	Jackson <i>et al.</i> (2002) <i>Biochemistry</i> , 41: 7565-7572	
	25	Kiefer <i>et al.</i> (1997) <i>Biochemistry</i> 36: 2084-2090	
	26	Kiefer <i>et al.</i> (1998) <i>Biochemistry</i> 37: 991-997	
	27	Klebig, <i>et al.</i> , (1995) <i>Proc. Natl. Acad. Sci. USA</i> 92:4728-4732	
	28	Michaud, <i>et al.</i> (1997) <i>J. Endocrinol</i> 155:207-209	
	29	PEP-NET (1999) 12(3): 1-4.	
	30	Quillan <i>et al.</i> (1998) <i>FEBS Lett.</i> 428, 59-62.	
	31	Willard <i>et al.</i> (1995) <i>Biochemistry</i> 34: 12341-12346.	
	32	Yang <i>et al.</i> (1999) <i>Mol. Endocrinol.</i> 13: 148-155.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.